Related Experiment Video
Updated: Sep 5, 2025
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia
Shubham Adhikary1, Meher Kaur Duggal1, Saraswathy Nagendran2
1Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, Vileparle-West, Mumbai-56, India.
Purpose Of Review:
Community-acquired bacterial pneumonia (CABP) continues to be a worldwide health concern since it is the major cause of mortality and hospitalisation worldwide. Increased macrolide resistance among Streptococcus pneumoniae and other infections has resulted in a significantly larger illness burden, which has been exacerbated by evolving demography and a higher prevalence of comorbid disorders. Owing to such circumstances, the creation of new antibiotic classes is critical.
Recent Findings:
Lefamulin, also referred to as BC-3781, is the primary pleuromutilin antibiotic which has been permitted for both intravenous and oral use in humans for the remedy of bacterial infections. It has shown activity against gram-positive bacteria including methicillin-resistant strains as well as atypical organisms which as often implicated in CABP. It has a completely unique mechanism of action that inhibits protein synthesis via way of means of stopping the binding of tRNA for peptide transfer. The C(14) side chain is responsible for its pharmacodynamic and antimicrobial properties, together with supporting in overcoming bacterial ribosomal resistance and mutations improvement amplifying the number of hydrogen bonds to the target site.
Summary:
This review aims to highlight the pre-existing treatment options and specific purposes to shed some light upon the development of a new drug lefamulin and its specifications and explore this novel drug's superior efficacy to already existing treatment strategies.
Insights
Community-acquired bacterial pneumonia (CABP) requires new treatments due to rising antibiotic resistance. Lefamulin, a novel pleuromutilin antibiotic, shows promise for treating CABP effectively.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Community-acquired bacterial pneumonia (CABP) remains a significant global health issue, causing widespread mortality and hospitalizations.
- Increasing macrolide resistance in Streptococcus pneumoniae and other pathogens exacerbates the burden of CABP.
- Demographic shifts and increased comorbidities further complicate CABP management, necessitating novel therapeutic agents.
Purpose of the Study:
- To review existing treatment options for CABP.
- To introduce the novel antibiotic lefamulin, detailing its specifications and mechanism of action.
- To explore lefamulin's efficacy compared to current CABP treatment strategies.
Main Methods:
- Literature review of existing CABP treatments.
- Analysis of preclinical and clinical data on lefamulin.
- Comparative efficacy assessment of lefamulin against established therapies.
Main Results:
- Lefamulin exhibits activity against Gram-positive bacteria, including methicillin-resistant strains, and atypical organisms implicated in CABP.
- Lefamulin possesses a unique mechanism of action, inhibiting protein synthesis by preventing tRNA binding to the peptide transfer site.
- The C(14) side chain of lefamulin contributes to its pharmacodynamic and antimicrobial properties, aiding in overcoming resistance mechanisms.
Conclusions:
- Lefamulin represents a promising new class of antibiotics for treating CABP.
- Its novel mechanism and broad spectrum of activity offer a valuable alternative to existing therapies, particularly in the face of rising antibiotic resistance.
- Further research and clinical application of lefamulin are warranted to address the growing challenge of CABP.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment